Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Synthorx, Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, ensuring a focused prosecution environment. The administrative scope is similarly narrow, with the activity occurring in 1 distinct art unit. This concentration suggests that the company's current USPTO engagement is limited to a specific technical niche within the biotechnology sector.
SKOKO III, JOHN JOSEPH is the busiest examiner for the company, currently overseeing 1 pending office action. Since there is only 1 pending office action in the entire portfolio, this examiner handles the totality of the company's active cases. The presence of only 1 distinct art unit and 1 distinct examiner indicates that the company is not currently managing multiple simultaneous patent applications. For a practitioner, the outcome of the portfolio's current standing rests on the interaction with SKOKO III, JOHN JOSEPH.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18524157 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | SKOKO III, JOHN JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18524157 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Non-Final OA | — | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynthorx, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John Joseph Skoko III has the most, with 1 of Synthorx, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
